linjc16/ctgov huggingface dataset:
Comparison of Blood Pressure Lowering Effect Between Fimasartan and Losartan

Study Overview
=================
Brief Summary
-----------------
Comparison of blood pressure lowering effect between Fimasartan and Losartan in the hypertensive patient during night and early morning time

Official Title
-----------------
Comparison of Blood Pressure Lowering Effect Between Fimasartan and Losartan in the Hypertensive Patient During Night and Early Morning Time

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Fimasartan
* Drug: Losartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject don't have Anti-hypertensive drug or who stop Anti-hypertensive drug during 2 weeks Office BP: over siSBP 140mmHg or si DBP 90mmHg 24hr ABPM: SBP 130mmHg or DBP 80mmHg (24 hour Average) Exclusion Criteria: Pregnant, trying to become pregnant or breast feeding Subject has Secondary Hypertension White coat Blood Pressure (Normal result of 24 hour ABPM)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fimasartan<br>Fimasartan 60mg, QD | Drug: Fimasartan<br> <br> * Other names: Kanarb;|
| Active Comparator: Losartan<br>Losartan 50mg, QD | Drug: Losartan<br> <br> * Other names: Cozaar;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood Pressure Lowering Effect through 24 ABPM | comparing blood pressure lowering effect between night and early morning | 24 hour |
A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors

Study Overview
=================
Brief Summary
-----------------
This study assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients. Gimatecan is administered orally twice per week, every 28 days, to adult patients with advanced solid tumors who have progressed despite standard therapy or for whom standard systemic therapy dose not exist.

Official Title
-----------------
A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors.

Conditions
-----------------
Advanced Solid Tumors

Intervention / Treatment
-----------------
* Drug: Gimatecan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Patients with histological or cytological confirmed advanced solid tumors, which progressed despite standard therapy or for whom no standard therapy exists Life expectancy of at least 3 months No dysfunction of bone marrow No major impairment of renal and hepatic function Exclusion criteria Gastrointestinal dysfunction, such as gastrectomy or malabsorption syndrome, that could alter absorption of the study drug Receipt of any investigational compound within the 28 days prior to the first dose of study drug, or failure to recover from the side effects of such prior therapy Receipt of other antineoplastic therapy including chemotherapy, hormone therapy, immunotherapy, radiation therapy within the 28 days Patients known to be HIV, or hepatitis B or C viruses positive, or patients with the presence of active or suspected acute or chronic uncontrolled infection Patients with a history of allergies to the camptothecin family of drugs Other protocol-defined inclusion/exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Gimatecan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability assessed by Adverse Events Characterization of the pharmacokinetic profile of gimatecan Anti-tumor activity assessed by Response Evaluation Criteria in Solid Tumors RECIST) |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gimatecan, topoisomerase I inhibitor, advanced solid tumors
Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to prove the bioequivalence of Anastrozole Tablet under fed conditions

Official Title
-----------------
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Anastrozole 1 mg Tablets Under Fed Conditions

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Drug: Anastrozole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to anastrozole or any comparable or similar product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Anastrozole|1 mg tablet|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bioequivalence determined by statistical comparison Cmax |  | 31 days |
One Dose Versus Three Weekly Doses of Benzathine Penicillin G for Patients With Early Syphilis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to observe the serological response to 1 or 3 weekly doses of benzathine penicillin G in patients with early syphilis.

Official Title
-----------------
Doctor of Medicine

Conditions
-----------------
Syphilis

Intervention / Treatment
-----------------
* Drug: Benzathine Penicillin G


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persons with confirmed early symptomatic syphilis (primary or secondary) or high-titer latent syphilis A rapid plasma reagin (RPR) test was positive, with a titer were 1:4 or higher. In addition, Treponema pallidum particle agglutination assay and/or fluorescent treponemal antibody absorption test were reactive. Exclusion Criteria: 1.Patients who were pregnancy, known allergy to penicillin, use of antibiotics active against syphilis during the preceding six months for symptomatic cases or during the preceding two years for asymptomatic cases, and concurrent illnesses requiring treatment with antibiotics effective against syphilis. 2. if RPR titers were found to be 1:4 or less or the T. pallidum particle agglutination test was nonreactive, participants were retrospectively excluded from the trial unless primary syphilis was confirmed by the finding of T. pallidum in ulcer exudates on direct immunofluorescence -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: single dose benzathine penicillin G.<br>single dose benzathine penicillin G. | Drug: Benzathine Penicillin G<br> <br> |
| Active Comparator: three doses of benzathine penicillin G.<br>three doses of benzathine penicillin G. | Drug: Benzathine Penicillin G<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rapid plasma reagin titers |  | up to 9 months after treatment |
Screening for Autism Spectrum Disorders Using Auditory Brainstem Responses

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to develop an Auditory Brainstem Response (ABR) based neurological screening method to detect increased risk for Autism Spectrum Disorders (ASD) and other neurological conditions in newborns.

Detailed Description
-----------------
In the proposed study, a screening method for neurological deficits, with an emphasis on its application to ASD, will be developed and its feasibility demonstrated. The proposed method will utilize high rate stimulation to acquire Auditory Brainstem Responses in order to determine peak latency and amplitude differences in children with ASD compared to non-ASD. Similarly to newborn hearing screening, the output of the screening method will provide an automated pass or refer outcome that can be used by a physician to determine if the child needs further evaluation.

Official Title
-----------------
Screening Device for Autism Spectrum Disorders Using High Stimulation Rate ABR With Continuous Loop Averaging Deconvolution

Conditions
-----------------
Autism Spectrum Disorder

Intervention / Treatment
-----------------
* Other: No Intervention Provided


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children with autism spectrum disorder diagnosis Normally developing age- and gender-matched controls Exclusion Criteria: Permanent or temporary hearing loss at the time of testing. Craniofacial abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 42 Months
Maximum Age: 54 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Autism Spectrum Disorders Group<br>Children identified as having Autism Spectrum Disorder Age: 3.5 to 4.5 years old | Other: No Intervention Provided<br>* No Intervention Provided<br>|
| Normal Control Group<br>Normal children without Autism Spectrum Disorder or other identified developmental disability Age: 3.5 to 4.5 years old | Other: No Intervention Provided<br>* No Intervention Provided<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ABR Peak V Latency | Auditory Brainstem Response (ABR) peak V latency measurement for the five stimulation rates used in the study. The latency is the time, measured in ms, from the onset of the stimulus to the generation of the response peak component. ABR peak V is the most prominent response peak component in humans. | One Week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Autism Spectrum Disorder
Causes of Nonattendance at Scheduled Outpatient Appointments

Study Overview
=================
Brief Summary
-----------------
Our aim was to identify the causes non-attendance at scheduled appointments at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA).

Detailed Description
-----------------
Nonattendance at scheduled appointments at outpatient clinics is a common problem in general medical practice, representing a significant cost to the health care system, and resulting in disruption of daily work planning.Nonattendance at medical appointments has consequences not only for doctors (as it requires a greater use of resources and time), but also for patients, because there may be deterioration in the quality of care, and dissatisfaction associated with delays in obtaining a new appointment.

Official Title
-----------------
Case-control Study: Causes of Nonattendance at Clinical Medicine Scheduled Outpatient Appointments in a University General Hospital

Conditions
-----------------
Appointments and Schedules, Outpatient Clinics, Hospital

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 17 years Adults who attended, did not attend and cancelled a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA) Exclusion Criteria: Refusal to register or to the informed consent process

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control: P<br>Patients who did attend a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA) | |
| Case: A<br>Patients who did not attend (A) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA) | |
| Control: C<br>Patients who cancelled (C) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Causes of nonattendance | Patients who did not attend a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA) | Between the scheduled appointment and 48 hours after | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Causes of cancelation | Patients who cancelled a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA) | Between the scheduled appointment and 48 hours after |
Progesterone Supplementation in Threatened Abortion

Study Overview
=================
Brief Summary
-----------------
To decide whether progesterone supplementation in threatened abortion is a sound practice.

Detailed Description
-----------------
This study was conducted at Obstetrics and Gynecology Department, Tanta University in the period from January 2018 to December 2018. Patients: Eligible patients (n=190) were randomly allocated into 2 groups; study group who will receive progesterone supplementation (Prog.group) and control group who will receive no treatment (place.group).

Official Title
-----------------
Progesterone Supplementation in Threatened Abortion: Is it a Sound Practice?

Conditions
-----------------
Threatened Abortion, Progesterone Resistance

Intervention / Treatment
-----------------
* Drug: Progesterone
* Drug: Placebos


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: threatened abortion diagnosed by history and ultrasound examination singleton viable fetus gestational age < 20 weeks closed normal length cervix. Exclusion Criteria: short cervix <2 cm Multiple pregnancy dead fetus open cervix ≥ 2cm history of cervical surgery refusal to participate.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Progesterone<br>received rectal progesterone suppositories 400 mg once daily | Drug: Progesterone<br>* received rectal progesterone suppositories 400 mg once daily<br>|
| Placebo Comparator: Control group<br>received placebo suppositories rectally once daily. | Drug: Placebos<br>* received placebo suppositories rectally once daily.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| relief of pain | questionnaire fulfilled by patient with yes or no questions | 3 weeks | 
| completion of pregnancy beyond 20 weeks | passing the age 20 weeks | 12 weeks | 
| Stoppage of bleeding | Cessation of bleeding | 3 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| abortion less than 20 weeks. | Abortion | 12 weeks |
Evaluation of the Repeatability and Reproducibility of Corneal Epithelial Thickness Mapping With iVue SD-OCT

Study Overview
=================
Brief Summary
-----------------
Evaluate the repeatability and reproducibility of iVue for measuring the total corneal thickness, the epithelial thickness, and the stromal thickness in normal subjects and patients with various corneal conditions.

Official Title
-----------------
Evaluation of the Repeatability and Reproducibility of Corneal Epithelial Thickness Mapping With iVue SD-OCT

Conditions
-----------------
Cornea

Intervention / Treatment
-----------------
* Device: Optical Coherence Tomography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal Able and willing to provide consent. Able and willing to complete required exams. Corneal conditions Able and willing to provide consent. Able and willing to complete required exams. History of refractive surgery, contact lens, dry eye or keratoconus. Exclusion Criteria: Normal History of refractive surgery, contact lens, dry eye or pathology. Blepharitis or meibomitis Unable to complete required exams. Corneal conditions Unable to complete required exams.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal<br>Not having any history of refractive surgery, contact lens, dry eye or pathology | Device: Optical Coherence Tomography<br> <br> |
| Corneal condition<br>History of refractive surgery, contact lens, dry eye or keratoconus | Device: Optical Coherence Tomography<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epithelial thickness |  | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Corneal thickness |  | Day 1 |
Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if a mobile sensing platform can passively and objectively detect the presence of clinically significant mood disorder symptomatology and symptom progression over time. Meeting this goal will allow for improved risk categorization, prediction of relapse, and measurement of disease progression in a lifetime prevalence population.

Official Title
-----------------
Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression

Conditions
-----------------
Depression, Bipolar Disorder

Intervention / Treatment
-----------------
* Other: Cogito Companion Mobile Phone Application


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 or older Have a smartphone and cell service plan, including voice and data, that meets the device requirements of the Mobile Sensing Platform. Enrolled in the MoodNetwork Exclusion Criteria: Report positively on the QIDS-SR suicide item during study intake Total score greater than 15 on the QIDS-SR during the screening process

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MDD-Single Episode<br>1. Subjects who have experienced 1 episode of major depressive disorder (MDD) in their lifetime. | Other: Cogito Companion Mobile Phone Application<br> <br> * Other names: Cogito Mobile Sensing Platform;|
| MDD-Recurrent<br>1. Subjects who have experienced 2 or more episodes of depressive disorder (MDD) in their lifetime. | Other: Cogito Companion Mobile Phone Application<br> <br> * Other names: Cogito Mobile Sensing Platform;|
| Bipolar Disorder<br>1. Subjects who have been diagnosed with bipolar disorder in their lifetime. | Other: Cogito Companion Mobile Phone Application<br> <br> * Other names: Cogito Mobile Sensing Platform;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Severity of MDD symptoms as assessed by QIDS SR |  | 6 months | 
| Severity of Mania symptoms as assessed by ASRM |  | 6 months |